肺免疫预后指数对转移性非小细胞肺癌患者的预后价值
该探索性汇总分析基于2013至2017年提交美国FDA的11项随机跨国临床试验数据,评估肺免疫预后指数(LIPI)与转移性非小细胞肺癌(mNSCLC)患者长期结局的关联。分析纳入3987例有可用数据的患者,结果显示基线LIPI良好评分与免疫检查点抑制剂(ICI)、靶向治疗(TT)和细胞毒化疗(CCT)组更优的总生存(OS)和无进展生存(PFS)均相关。
要点
- 基线LIPI良好评分与ICI、TT和CCT组更优的OS和PFS相关。
- LIPI基于dNLR和LDH水平计算,是不依赖治疗方式的预后生物标志物。
- 需进一步前瞻性试验明确LIPI评分的临床角色。
核心结论
- 基线LDH水平和dNLR是mNSCLC患者重要的预后生物标志物,与治疗方式无关。
- LIPI评分在ICI、TT和CCT治疗患者中均与OS和PFS相关。
- 需进一步前瞻性临床试验信息以更好定义LIPI评分的作用。
研究设计与样本
- 共4914例mNSCLC患者,其中3987例有可用数据。
- LIPI评分根据dNLR和LDH水平计算,分为良好、中等和不良复合评分。
- 采用多变量Cox比例风险模型生成PFS和OS风险比。
主要发现
- 在5项ICI试验的2440例患者中,1368例接受ICI,1072例接受CCT。
- 在6项TT试验的1547例患者中,1110例接受TT,437例接受CCT。
- 良好LIPI评分与接受ICI患者更优OS相关(HR 0.34,95% CI 0.28-0.42)。
- 良好LIPI评分与接受TT患者更优OS相关(HR 0.28,95% CI 0.21-0.37)。
- 良好LIPI评分与接受CCT患者更优OS相关(ICI试验中HR 0.49,95% CI 0.40-0.60;TT试验中HR 0.41,95% CI 0.27-0.61)。
临床怎么用
- 基线LIPI评分可用于mNSCLC患者预后分层,不受治疗方式影响。
- LIPI良好评分提示OS和PFS更优,不良评分提示预后较差。
局限性
- 为探索性汇总分析,需前瞻性临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous studies have suggested the importance of the baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level as prognostic markers. The lung immune prognostic index (LIPI) was shown to be associated with progression-free survival (PFS) and overall survival (OS) among patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs) but not cytotoxic chemotherapy (CCT). OBJECTIVE: To determine whether the LIPI is associated with long-term outcomes in pooled analyses of clinical studies of ICI and targeted therapy (TT) for patients with mNSCLC. DESIGN, SETTING, AND PARTICIPANTS: An exploratory pooled analysis was performed of the LIPI on data from 11 randomized clinical multinational trials evaluating ICIs and TT submitted to the US Food and Drug Administration between January 1, 2013, and December 31, 2017, for 4914 patients with mNSCLC. Lung immune prognostic index scores were calculated based on the dNLR and the LDH level per previous publications to generate good, intermediate, and poor composite scores. Multivariable Cox proportional PFS and OS hazard ratios were generated for the dNLR, the LDH level, age, smoking status, histologic characteristics, and Eastern Cooperative Oncology Group performance score. MAIN OUTCOMES AND MEASURES: Overall survival and PFS and their association with good, intermediate, or poor prognostic LIPI scores. RESULTS: Eleven mNSCLC randomized trials were analyzed, including 3987 patients with available data. In 5 ICI trials comprising 2440 patients, 1368 patients received ICIs and 1072 patients received CCT. In 6 TT trials comprising 1547 patients, 1110 patients received TT and 437 patients received CCT. A good LIPI score was associated with better OS among patients receiving ICIs (hazard ratio, 0.34; 95% CI, 0.28-0.42), TT (hazard ratio, 0.28; 95% CI, 0.21-0.37), and CCT (hazard ratio, 0.49; 95% CI, 0.40-0.60 in ICI trials; hazard ratio, 0.41; 95% CI, 0.27-0.61 in TT trials) than those with poor LIPI scores. Similar findings were observed in terms of PFS (ICIs: hazard ratio, 0.59; 95% CI, 0.48-0.72; TT: hazard ratio, 0.46; 95% CI, 0.37-0.57; and CCT: hazard ratio, 0.56; 95% CI, 0.45-0.68 in ICI trials; hazard ratio, 0.51; 95% CI, 0.38-0.69 in TT trials). CONCLUSIONS AND RELEVANCE: The baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC. As further prospective clinical trial information is collected, the role of the LIPI score can be better defined.
引用
- Kazandjian D, Gong Y, Keegan P, et al. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019. PMID: 31343662. doi:10.1001/jamaoncol.2019.1747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。